Lipad Inj. 20mg
Now Target & Treat with Confidence Lipad 20mg (PEGylated Liposomal Doxorubicin) A GAME-CHANGER IN ONCOLOGY Lipad (PLD) offers a targeted, effective, and safer chemotherapy option for patients with various cancers,
Lipad Injection 20mg
Generic Name: Doxorubicin HCL PEGylated Liposome Injection
Indications
- AIDs related Kaposi’s Sarcoma: as a first-line systemic chemotherapy, or as a second-line chemotherapy drug for patients with progression, or who cannot tolerate the combination of two or more of the following drugs: vincristine, bleomycin and doxorubicin (other anthracycline antibiotics).
- Breast Cancer: as monotherapy or combination therapy.
- Ovarian Cancer: as a 2nd line therapy as combination therapy or as monotherapy for platin resistant cases.
- Multiple Myeloma: in combination with Bortezomib.
- Guidelines also recommend the treatment of Lymphoma, uterine tumors, bone and soft tissue sarcomas etc.
Strength:
20mg; 10 ml
Pack Size:
Single-use vial
Dosage Form:
Sterile injectable solution
Categories:
Pharmaceuticals
Therapeutic Class:
Anthracyclines